New York, New York, USA, November 17, 2026
Ichnos Glenmark Innovation, Inc. (IGI) has announced the submission of an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) for ISB 2301, an investigational multispecific immune cell activator being developed to target solid tumors. The company describes ISB 2301 as a potential first-in-class pentaspecific biologic designed to recognise three tumour-associated antigens while engaging two major immune cell populations: T cells and natural killer (NK) cells. By bringing multiple tumour-targeting and immune-activating functions together in one molecule, the candidate is intended to address the biological complexity and immune-suppressive characteristics that can make solid tumours difficult to treat. Following the IND submission, IGI plans to initiate a Phase 1 clinical trial in patients with solid tumours in 2027, subject to the necessary regulatory requirements.
ISB 2301 Combines Five Binding Specificities
ISB 2301 has been engineered to combine five distinct binding specificities within a single therapeutic molecule. Three of these are directed against tumour-associated antigens (TAAs), which are molecular targets expressed by cancer cells. The remaining two are designed to engage and activate T cells and NK cells, both of which play important roles in the body’s immune response against cancer. This multispecific design aims to bring immune effector cells into the tumour-targeting process while recognising multiple tumour-associated markers. Targeting three antigens is intended to address tumour heterogeneity, a characteristic in which cancer cells within the same tumour or across different tumour sites may express different molecular features. Engaging both T cells and NK cells also provides complementary immune mechanisms rather than relying on a single immune-cell population. The approach is being investigated as a way to improve tumour recognition and immune activity in solid cancers, where the tumour microenvironment can limit the effectiveness of immune-based treatments. However, the proposed benefits remain under investigation and will need to be demonstrated in clinical studies.
BEAT Platform Supports Multiple Immune-Activating Mechanisms
The candidate was developed using IGI’s proprietary BEAT® Multispecific Platform, which is designed to support the engineering of biologics with multiple targeting and immune-engaging functions. According to the company, ISB 2301 is intended to activate complementary mechanisms, including antibody-dependent cellular cytotoxicity (ADCC), checkpoint inhibition and the induction of a sustained type 1 immune response. ADCC is an immune mechanism through which antibody-bound target cells can be recognised and destroyed by immune effector cells, including NK cells. Checkpoint inhibition is intended to help counter signals that suppress immune activity, while a type 1 immune response is associated with cellular immune functions involved in controlling infections and cancer. Integrating these mechanisms into one molecule is central to the candidate’s development strategy. IGI aims to use this design to address multiple aspects of tumour recognition and immune activation simultaneously. The company has reported that preclinical studies demonstrated a favourable pharmacokinetic and tolerability profile in non-human primates. These findings provide a basis for further investigation but do not establish safety or efficacy in humans.
Phase 1 Clinical Trial Planned for 2027
Following the IND submission, IGI plans to begin a Phase 1 study in patients with solid tumours in 2027. The planned early-stage clinical evaluation is expected to investigate the candidate’s safety, tolerability, pharmacokinetics and pharmacodynamics, as well as its preliminary anti-tumour activity. Phase 1 studies are an important first step in assessing an investigational therapy in humans and identifying an appropriate dose and safety profile for further development. The study will help determine whether the biological activity observed in preclinical research can translate into a clinical setting. IGI has not announced detailed trial enrolment numbers, specific tumour types or a clinical trial start date in this announcement. Lida Pacaud, M.D., President and Chief Executive Officer of IGI, described the IND submission as an important milestone in advancing the company’s multispecific oncology pipeline into clinical development. The announcement also highlights IGI’s broader work in multispecific cancer therapies. Its pipeline includes ISB 2001, an investigational CD38 × BCMA × CD3 trispecific T-cell engager being evaluated in a Phase 1 study for patients with heavily pretreated relapsed or refractory multiple myeloma. The company reports that this programme has demonstrated clinical proof of concept, including promising anti-tumour activity and a favourable safety profile in the investigational setting.
The IND submission for ISB 2301 marks a development milestone, but it should not be interpreted as FDA approval or confirmation that clinical testing has begun. ISB 2301 remains an investigational therapy, and its potential role in treating solid tumours will depend on the results of future clinical trials and regulatory review. The planned Phase 1 programme will be an important next step in assessing whether this five-target multispecific approach can offer a meaningful therapeutic strategy for patients with advanced solid cancers.
Source: Ichnos Glenmark Innovation press release



